Massachusetts general hospital Covid-19 registry reveals two distinct populations of hospitalized patients by race and ethnicity
- PMID: 33351826
- PMCID: PMC7755195
- DOI: 10.1371/journal.pone.0244270
Massachusetts general hospital Covid-19 registry reveals two distinct populations of hospitalized patients by race and ethnicity
Abstract
Objective: To evaluate differences by race/ethnicity in clinical characteristics and outcomes among hospitalized patients with Covid-19 at Massachusetts General Hospital (MGH).
Methods: The MGH Covid-19 Registry includes confirmed SARS-CoV-2-infected patients hospitalized at MGH and is based on manual chart reviews and data extraction from electronic health records (EHRs). We evaluated differences between White/Non-Hispanic and Hispanic patients in demographics, complications and 14-day outcomes among the N = 866 patients hospitalized with Covid-19 from March 11, 2020-May 4, 2020.
Results: Overall, 43% of patients hospitalized with Covid-19 were women, median age was 60.4 [IQR = (48.2, 75)], 11.3% were Black/non-Hispanic and 35.2% were Hispanic. Hispanic patients, representing 35.2% of patients, were younger than White/non-Hispanic patients [median age 51y; IQR = (40.6, 61.6) versus 72y; (58.0, 81.7) (p<0.001)]. Hispanic patients were symptomatic longer before presenting to care (median 5 vs 3d, p = 0.039) but were more likely to be sent home with self-quarantine than be admitted to hospital (29% vs 16%, p<0.001). Hispanic patients had fewer comorbidities yet comparable rates of ICU or death (34% vs 36%). Nonetheless, a greater proportion of Hispanic patients recovered by 14 days after presentation (62% vs 45%, p<0.001; OR = 1.99, p = 0.011 in multivariable adjusted model) and fewer died (2% versus 18%, p<0.001).
Conclusions: Hospitalized Hispanic patients were younger and had fewer comorbidities compared to White/non-Hispanic patients; despite comparable rates of ICU care or death, a greater proportion recovered. These results have implications for public health policy and the design and conduct of clinical trials.
Conflict of interest statement
I have read the journal’s policy and the authors of this manuscript have the following competing interests: SAL receives sponsored research support from Bristol Myers Squibb/Pfizer, Bayer AG, Boehringer Ingelheim, and Fitbit, and has consulted for Bristol Myers Squibb/Pfizer and Bayer AG. SAL also participates in a research collaboration with IBM. JH reports personal fees from Cambridge Health Alliance, Community Servings, Columbia University, DaVita,University of Southern California, and from Delta Health Alliance, outside the submitted work. All other authors declare no conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
References
-
- Massachusetts Department of Public Health COVID-19 Dashboard—Friday, June 05, 2020. Commonwealth of Massachusetts Department of Public Health; 2020. Available: https://www.mass.gov/doc/covid-19-dashboard-june-5-2020/download
-
- Massachusetts Department of Public Health—COVID-19 cases by city/town in MA—May 13, 2020. Commonwealth of Massachusetts Department of Public Health; Available: https://www.mass.gov/doc/confirmed-covid-19-cases-in-ma-by-citytown-janu...
-
- U.S. Census Bureau. American Community Survey. 2017. Available: https://datausa.io/profile/geo/chelsea-ma/
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
